Compare GNLN & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLN | OGEN |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 2.7M |
| IPO Year | 2019 | 2010 |
| Metric | GNLN | OGEN |
|---|---|---|
| Price | $3.36 | $0.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 55.3K | 40.9K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,275,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.01 | $0.11 |
| 52 Week High | $7.73 | $9.16 |
| Indicator | GNLN | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 47.51 |
| Support Level | $2.91 | $0.56 |
| Resistance Level | $3.42 | $0.66 |
| Average True Range (ATR) | 0.40 | 0.04 |
| MACD | -0.29 | 0.00 |
| Stochastic Oscillator | 1.67 | 44.49 |
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). It serves specialty retailers, smoke shops, head shops, convenience stores, and consumers. Geographically, it operates in United States, Canada, and Europe. It derives majority revenue from the United States. Its two operating segments are: Wholesale and Distribution, which includes legacy e-commerce and drop-ship operations; and Digital Assets, which includes digital asset treasury activities including acquisition, staking and validator participation related to BERA.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.